Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Esma Yolcu
University of Louisville, Department: Microbiology/immun/virology
Should you be removed from our database? Contact us at [email protected]. Read more below.
FasCure
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Individual holds equity position in FasCure. If the results of the award are successful, FasCure would be in a favorable position to license any resulting technology. As FasCure is a start-up company, the actual value cannot be readily determined.
Targeted delivery of immunomodulatory biologics for induction of immune privilege to allogeneic pancreatic islet grafts
PROJECT NARRATIVE Type 1 diabetes (T1D) is a chronic autoimmune disorder that affects more than 1% of the population worldwide. Transplantation of pancreatic islets producing insulin has been shown to be an effective treatment. However, graft recipients are required to take immunosuppressive drugs, which has significant adverse effects, during their life to control rejection. The primary objective of this proposal is to establish and test a graft- targeted immunomodulatory protocol delivered using advanced biomaterials that sustains long-term islet graft survival and function in the absence of any immunosuppression in various relevant pre-clinical models, including a humanized mouse model. If effective, this approach will have immediate and important implications for the use of allogeneic islets for the treatment of T1D in humans. �
Filed on June 29, 2017.
Tell us what you know about Esma Yolcu's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Esma Yolcu”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Esma Yolcu | University of Louisville | Conflict of Interest | FasCure Therapeutics | Value cannot be readily determined |
| Esma Yolcu | University of Louisville | Conflict of Interest | FasCure | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.